Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15
Sponsored by Pfizer
About this trial
Last updated 2 years ago
Study ID
Status
Type
Phase
Placebo
Accepting
Not accepting
Trial Timing
Ended 2 months ago
What is this trial about?
What are the Participation Requirements?
Key Inclusion Criteria:
- Documented active diagnosis of non-small cell lung, pancreatic, colorectal cancer
- Cachexia defined by Fearon criteria of weight loss
- Serum GDF-15 concentrations
- Signed informed consent
- ECOG PS ≤3 with life expectancy of at least 4 months to be able to complete Part A.
Key Exclusion Criteria:
- Receiving tube feedings or parenteral nutrition at the time of Screening or
Randomization.
- Current active reversible causes of decreased food intake.
- Cachexia caused by other reasons.
- History of allergic or anaphylactic reaction to any therapeutic or diagnostic
monoclonal antibody.
- inadequate liver function
- renal disease requiring dialysis